EntryPoint Capital’s ResMed RMD Stock Holding History

EntryPoint Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$657K	Buy	+2,926	New	+$729K	0.19%	159
2025 Q3	–	Sell	-780	Closed	-$201K	–	845
2025 Q2	$201K	Buy	+780	New	+$186K	0.1%	484
2025 Q1	–	Sell	-1,518	Closed	-$347K	–	914
2024 Q4	$347K	Buy	+1,518	New	+$366K	0.15%	282
2024 Q2	–	Sell	-626	Closed	-$124K	–	1509
2024 Q1	$124K	Buy	626 +188	+43%	+$34.4K	0.11%	303
2023 Q4	$75.3K	Buy	+438	New	+$67.3K	0.07%	532

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EntryPoint Capital's RMD Position: Q1 2026 in Review

EntryPoint Capital opened a new position in ResMed (RMD) in Q1 2026: 2,926 shares worth $657K. The stake represents 0.19% of the portfolio and ranks #159 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in RMD as recently as Q2 2025.

EntryPoint Capital first reported a position in RMD in Q4 2023 and has held it in 5 quarters since. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

EntryPoint Capital held 2,926 shares of ResMed worth $657K as of Q1 2026.
ResMed was a new EntryPoint Capital position in Q1 2026.
ResMed made up 0.19% of EntryPoint Capital's portfolio in Q1 2026, its #159 holding.
EntryPoint Capital first reported a position in ResMed in Q4 2023 and has held it in 5 quarters since.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.